Journal of Pathology and Translational Medicine

Ja Seong Bae

2 Articles

Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans: Sue Youn Kim, Taeeun Kim, Kwangsoon Kim, Ja Seong Bae, Jeong Soo Kim, Chan Kwon Jung; J Pathol Transl Med. 2020;54(4):310-317. Published online June 15, 2020; DOI: https://doi.org/10.4132/jptm.2020.05.12

5,385 View
149 Download
15 Citations

Background
The presence of telomerase reverse transcriptase (TERT) promoter mutations have been associated with a poor prognosis in patients with papillary thyroid carcinomas (PTC). The frequency of TERT promoter mutations varies widely depending on the population and the nature of the study.
Methods
Data were prospectively collected in 724 consecutive patients who underwent thyroidectomy for PTC from 2018 to 2019. Molecular testing for BRAF V600E and TERT promoter mutations was performed in all cases.
Results
TERT promoter alterations in two hotspots (C228T and C250T) and C216T were found in 16 (2.2%) and 4 (0.6%) of all PTCs, respectively. The hotspot mutations were significantly associated with older age at diagnosis, larger tumor size, extrathyroidal extension, higher pathologic T category, lateral lymph node metastasis, and higher American Thyroid Association recurrence risk. The patients with C216T variant were younger and had a lower American Thyroid Association recurrence risk than those with hotspot mutations. Concurrent BRAF V600E was found in 19 of 20 cases with TERT promoter mutations. Of 518 microcarcinomas measuring ≤1.0 cm in size, hotspot mutations and C216T variants were detected in five (1.0%) and three (0.6%) cases, respectively.
Conclusions
Our study indicates a low frequency of TERT promoter mutations in Korean patients with PTC and supports previous findings that TERT promoter mutations are more common in older patients with unfavorable clinicopathologic features and BRAF V600E. TERT promoter mutations in patients with microcarcinoma are uncommon and may have a limited role in risk stratification. The C216T variant seems to have no clinicopathologic effect on PTC.

Citations

Citations to this article as recorded by

BRAF V600E mutation test on fine‐needle aspiration specimens of thyroid nodules: Clinical correlations for 4600 patients
Huang Chen, Aiping Song, Ye Wang, Yifan He, Jie Tong, Jinxi Di, Chun Li, Zhongren Zhou, Xiaopin Cai, Dingrong Zhong, Jiping Da
Cancer Medicine.2022; 11(1): 40. CrossRef
Clinicopathological indicators for TERT promoter mutation in papillary thyroid carcinoma
Hee Young Na, Hyeong Won Yu, Woochul Kim, Jae Hoon Moon, Chang Ho Ahn, Sang Il Choi, Yeo Koon Kim, June Young Choi, So Yeon Park
Clinical Endocrinology.2022;[Epub] CrossRef
A Systematic Review and Meta-analysis on the Occurrence of Biomarker Mutation in Colorectal Cancer among the Asian Population
Hafeez Afolabi, Salzihan Md Salleh, Zaidi Zakaria, Ch’ng Ewe Seng, Siti Norasikin Binti Mohd Nafil, Ahmad Aizat Bin Abdul Aziz, Yusuf Wada, Ahmad Irekeola, Syed Sameer Aga
BioMed Research International.2022; 2022: 1. CrossRef
A Significance of Concomitant BRAFV600E and TERT Mutations in Polish Patients with Papillary Thyroid Microcarcinoma: A Retrospective Cohort Study Based on 430 Cases
Artur Kuchareczko, Janusz Kopczyński, Artur Kowalik, Kinga Hińcza-Nowak, Agnieszka Walczyk, Iwona Pałyga, Tomasz Trybek, Monika Szymonek, Danuta Gąsior-Perczak, Klaudia Gadawska-Juszczyk, Estera Mikina, Izabela Płachta, Agnieszka Suligowska, Agnieszka Płu
Thyroid.2022; 32(11): 1372. CrossRef
Machine learning for identifying benign and malignant of thyroid tumors: A retrospective study of 2,423 patients
Yuan-yuan Guo, Zhi-jie Li, Chao Du, Jun Gong, Pu Liao, Jia-xing Zhang, Cong Shao
Frontiers in Public Health.2022;[Epub] CrossRef
TERT Promoter and BRAF V600E Mutations in Papillary Thyroid Cancer: A Single-Institution Experience in Korea
Min Jhi Kim, Jin Kyong Kim, Gi Jeong Kim, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Woong Youn Chung, Daham Kim, Kee-Hyun Nam
Cancers.2022; 14(19): 4928. CrossRef
Frequency of TERT Promoter Mutations in Real-World Analysis of 2,092 Thyroid Carcinoma Patients (Endocrinol Metab 2022;37:652-63, Heera Yang et al.)
Sue Youn Kim, Chan Kwon Jung
Endocrinology and Metabolism.2022; 37(6): 947. CrossRef
Frequency of TERT Promoter Mutations in Real-World Analysis of 2,092 Thyroid Carcinoma Patients (Endocrinol Metab 2022;37:652-63, Heera Yang et al.)
Hyunju Park, Jae Hoon Chung
Endocrinology and Metabolism.2022; 37(6): 949. CrossRef
Molecular Pathology of Non-familial Follicular Epithelial–Derived Thyroid Cancer in Adults: From RAS/BRAF-like Tumor Designations to Molecular Risk Stratification
Paula Soares, Antónia Afonso Póvoa, Miguel Melo, João Vinagre, Valdemar Máximo, Catarina Eloy, José Manuel Cameselle-Teijeiro, Manuel Sobrinho-Simões
Endocrine Pathology.2021; 32(1): 44. CrossRef
Clinicopathological Characteristics and Recurrence-Free Survival of Rare Variants of Papillary Thyroid Carcinomas in Korea: A Retrospective Study
Mijin Kim, Sun Wook Cho, Young Joo Park, Hwa Young Ahn, Hee Sung Kim, Yong Joon Suh, Dughyun Choi, Bu Kyung Kim, Go Eun Yang, Il-Seok Park, Ka Hee Yi, Chan Kwon Jung, Bo Hyun Kim
Endocrinology and Metabolism.2021; 36(3): 619. CrossRef
Clinical Application of TERT Promoter Mutations in Urothelial Carcinoma
Yujiro Hayashi, Kazutoshi Fujita, George J. Netto, Norio Nonomura
Frontiers in Oncology.2021;[Epub] CrossRef
MicroRNA Profile for Diagnostic and Prognostic Biomarkers in Thyroid Cancer
Jong-Lyul Park, Seon-Kyu Kim, Sora Jeon, Chan-Kwon Jung, Yong-Sung Kim
Cancers.2021; 13(4): 632. CrossRef
Prospective Analysis of TERT Promoter Mutations in Papillary Thyroid Carcinoma at a Single Institution
Yun-Suk Choi, Seong-Woon Choi, Jin-Wook Yi
Journal of Clinical Medicine.2021; 10(10): 2179. CrossRef
Significance of telomerase reverse-transcriptase promoter mutations in differentiated thyroid cancer
Hung-Fei Lai, Chi-Yu Kuo, Shih-Ping Cheng
Formosan Journal of Surgery.2021; 54(5): 171. CrossRef
Early Diagnosis of Low-Risk Papillary Thyroid Cancer Results Rather in Overtreatment Than a Better Survival
Jolanta Krajewska, Aleksandra Kukulska, Malgorzata Oczko-Wojciechowska, Agnieszka Kotecka-Blicharz, Katarzyna Drosik-Rutowicz, Malgorzata Haras-Gil, Barbara Jarzab, Daria Handkiewicz-Junak
Frontiers in Endocrinology.2020;[Epub] CrossRef

Classic Papillary Thyroid Carcinoma with Tall Cell Features and Tall Cell Variant Have Similar Clinicopathologic Features: Woo Jin Oh, Young Sub Lee, Uiju Cho, Ja Seong Bae, Sohee Lee, Min Hee Kim, Dong Jun Lim, Gyeong Sin Park, Youn Soo Lee, Chan Kwon Jung; Korean J Pathol. 2014;48(3):201-208. Published online June 26, 2014; DOI: https://doi.org/10.4132/KoreanJPathol.2014.48.3.201

14,115 View
115 Download
29 Citations

Abstract PDF

Background

The tall cell variant of papillary thyroid carcinoma (TCVPTC) is more aggressive than classic papillary thyroid carcinoma (PTC), but the percentage of tall cells needed to diagnose TCVPTC remains controversial. In addition, little is known about the clinicopathologic features of classic PTC with tall cell features (TCF).

Methods

We retrospectively selected and reviewed the clinicopathologic features and presence of the BRAF mutation in 203 cases of classic PTC, 149 cases of classic PTC with TCF, and 95 cases of TCVPTCs, which were defined as PTCs having <10%, 10-50%, and ≥50% tall cells, respectively.

Results

TCVPTCs and classic PTCs with TCF did not vary significantly in clinicopathologic characteristics such as pathologic (p) T stage, extrathyroidal extension, pN stage, lateral lymph node metastasis, or BRAF mutations; however, these features differed significantly in TCVPTCs and classic PTCs with TCF in comparison to classic PTCs. Similar results were obtained in a subanalysis of patients with microcarcinomas (≤1.0 cm in size).

Conclusions

Classic PTCs with TCF showed a similar BRAF mutation rate and clinicopathologic features to TCVPTCs, but more aggressive characteristics than classic PTCs.

Citations

Citations to this article as recorded by

CD56 Expression in Papillary Thyroid Carcinoma Is Highly Dependent on the Histologic Subtype: A Potential Diagnostic Pitfall
Uiju Cho, Yourha Kim, Sora Jeon, Chan Kwon Jung
Applied Immunohistochemistry & Molecular Morphology.2022; 30(5): 389. CrossRef
Aggressive histopathological variants of papillary thyroid carcinoma, diagnostic challenge, and clinical significance—A case series
PK Pravanya, KR Anila, Shaji Thomas, A Sreekumar, K Jayasree
Medical Journal of Dr. D.Y. Patil Vidyapeeth.2022;[Epub] CrossRef
Tall cell variant papillary thyroid carcinoma impacts disease-free survival at the 10 % cut-point on multivariate analysis
Shabnam Samankan, Leah Militello, Gabriella Seo, Sedef Everest, Quinn O'Malley, Sarah L. Spaulding, Monica Xing, Ammar Matloob, John Beute, Raymond Chai, Scott Doyle, Mark L. Urken, Margaret Brandwein-Weber
Pathology - Research and Practice.2022; 236: 154012. CrossRef
A population-based study of the three major variants of papillary thyroid carcinoma
Junming Xu, Yingying Zhang, Jun Liu, Shenglong Qiu, Min Wang
Journal of International Medical Research.2021; 49(2): 030006052098461. CrossRef
Tall cell percentage alone in PTC without aggressive features should not guide patients’ clinical management
Anello Marcello Poma, David Viola, Elisabetta Macerola, Agnese Proietti, Eleonora Molinaro, Dario De Vietro, Rossella Elisei, Gabriele Materazzi, Paolo Miccoli, Fulvio Basolo, Clara Ugolini
The Journal of Clinical Endocrinology & Metabolism.2021; 106(10): e4109. CrossRef
Molecular Pathology of Non-familial Follicular Epithelial–Derived Thyroid Cancer in Adults: From RAS/BRAF-like Tumor Designations to Molecular Risk Stratification
Paula Soares, Antónia Afonso Póvoa, Miguel Melo, João Vinagre, Valdemar Máximo, Catarina Eloy, José Manuel Cameselle-Teijeiro, Manuel Sobrinho-Simões
Endocrine Pathology.2021; 32(1): 44. CrossRef
Deep Neck Infection: Atypical Presentation of Papillary Thyroid Cancer
Apichana Mahattanapreut, Rangsima Aroonroch, Chalermchai Chintrakarn, Chutintorn Sriphrapradang, Dinesh K. Chhetri
Case Reports in Otolaryngology.2021; 2021: 1. CrossRef
The evolving concept of aggressive histological variants of differentiated thyroid cancer
Juan C. Hernandez-Prera
Seminars in Diagnostic Pathology.2020; 37(5): 228. CrossRef
Papillary Thyroid Cancer—Aggressive Variants and Impact on Management: A Narrative Review
Andrés Coca-Pelaz, Jatin P. Shah, Juan C. Hernandez-Prera, Ronald A. Ghossein, Juan P. Rodrigo, Dana M. Hartl, Kerry D. Olsen, Ashok R. Shaha, Mark Zafereo, Carlos Suarez, Iain J. Nixon, Gregory W. Randolph, Antti A. Mäkitie, Luiz P. Kowalski, Vincent Van
Advances in Therapy.2020; 37(7): 3112. CrossRef
Contemporary evaluation and management of tall cell variant of papillary thyroid carcinoma
Sara Cartwright, Abbey Fingeret
Current Opinion in Endocrinology, Diabetes & Obesity.2020; 27(5): 351. CrossRef
Le carcinome papillaire de la thyroïde avec contingent à cellules hautes : facteurs pronostiques
I. Riahi, H. Jaafoura, H. Saibi, E. Chebil, I. Ben Nacef, M. Ksentini, T. Ben Ghachem, R. Lahiani, M. Ben Salah
Annales d'Endocrinologie.2020; 81(4): 345. CrossRef
Updates in the Pathologic Classification of Thyroid Neoplasms: A Review of the World Health Organization Classification
Yanhua Bai, Kennichi Kakudo, Chan Kwon Jung
Endocrinology and Metabolism.2020; 35(4): 696. CrossRef
Tall Cell Variant of Papillary Thyroid Carcinoma: Impact of Change in WHO Definition and Molecular Analysis
Kristine S. Wong, Sara E. Higgins, Ellen Marqusee, Matthew A. Nehs, Trevor Angell, Justine A. Barletta
Endocrine Pathology.2019; 30(1): 43. CrossRef
Histopatological and molecular genetic characteristics of clinically aggressive variants of papillary thyroid carcinoma
A. V. Bogolyubova, A. Yu. Abrosimov, L. S. Selivanova, P. V. Belousov
Arkhiv patologii.2019; 81(1): 46. CrossRef
Papillary Thyroid Cancers with Focal Tall Cell Change are as Aggressive as Tall Cell Variants and Should Not be Considered as Low-Risk Disease
Pim J. Bongers, Wouter P. Kluijfhout, Raoul Verzijl, Mattan Lustgarten, Marloes Vermeer, David P. Goldstein, Karen Devon, Lorne E. Rotstein, Sylvia L. Asa, James D. Brierley, Richard W. Tsang, Shereen Ezzat, Menno R. Vriens, Ozgur Mete, Jesse D. Pasternak
Annals of Surgical Oncology.2019; 26(8): 2533. CrossRef
A case-based approach to aggressive variants of papillary thyroid carcinoma with literature review
JosephAntoine Flordelis Chatto, AnnetteLaurente Salillas
Thyroid Research and Practice.2019; 16(3): 128. CrossRef
Clinically Relevant Prognostic Parameters in Differentiated Thyroid Carcinoma
Tyler Janovitz, Justine A. Barletta
Endocrine Pathology.2018; 29(4): 357. CrossRef
Prediction of novel target genes and pathways involved in tall cell variant papillary thyroid carcinoma
Fada Xia, Bo Jiang, Yong Chen, Xin Du, Yao Peng, Wenlong Wang, Zhuolu Wang, Xinying Li
Medicine.2018; 97(51): e13802. CrossRef
Papillary thyroid carcinoma with tall cell features is as aggressive as tall cell variant: a meta-analysis
Huy Gia Vuong, Nguyen Phuoc Long, Nguyen Hoang Anh, Tran Diem Nghi, Mai Van Hieu, Le Phi Hung, Tadao Nakazawa, Ryohei Katoh, Tetsuo Kondo
Endocrine Connections.2018; 7(12): R286. CrossRef
TERT Promoter Mutation in an Aggressive Cribriform Morular Variant of Papillary Thyroid Carcinoma
Eun Ji Oh, Sohee Lee, Ja Seong Bae, Yourha Kim, Sora Jeon, Chan Kwon Jung
Endocrine Pathology.2017; 28(1): 49. CrossRef
Update on the cytologic features of papillary thyroid carcinoma variants
Marc Pusztaszeri, Manon Auger
Diagnostic Cytopathology.2017; 45(8): 714. CrossRef
Molecular correlates and rate of lymph node metastasis of non-invasive follicular thyroid neoplasm with papillary-like nuclear features and invasive follicular variant papillary thyroid carcinoma: the impact of rigid criteria to distinguish non-invasive f
Uiju Cho, Ozgur Mete, Min-Hee Kim, Ja Seong Bae, Chan Kwon Jung
Modern Pathology.2017; 30(6): 810. CrossRef
BRAF-positive paucicellular variant of anaplastic carcinoma in the presence of tall cell variant papillary thyroid cancer
O. V. Dolzhansky, E. M. Paltseva, D. N. Khmelkova, F. A. Konovalov, I. V. Kanivets, A. V. Lavrov, D. V. Pyankov, S. A. Korostelev, O. A. Levendyuk, V. M. Pominalnaya, D. N. Fedorov
Arkhiv patologii.2017; 79(3): 27. CrossRef
A comparison of the clinicopathological features and prognoses of the classical and the tall cell variant of papillary thyroid cancer: a meta-analysis
Zeming Liu, Wen Zeng, Tianwen Chen, Yawen Guo, Chao Zhang, Chunping Liu, Tao Huang
Oncotarget.2017; 8(4): 6222. CrossRef
Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation
Ja Seong Bae, Yourha Kim, Sora Jeon, Se Hee Kim, Tae Jung Kim, Sohee Lee, Min-Hee Kim, Dong Jun Lim, Youn Soo Lee, Chan Kwon Jung
Diagnostic Pathology.2016;[Epub] CrossRef
Tall cell variant of papillary thyroid carcinoma: current evidence on clinicopathologic features and molecular biology
Xiaofei Wang, Wenli Cheng, Chongqing Liu, Jingdong Li
Oncotarget.2016; 7(26): 40792. CrossRef
The Warthin-Like Variant of Papillary Thyroid Carcinoma: A Comparison with Classic Type in the Patients with Coexisting Hashimoto’s Thyroiditis
Min-kyung Yeo, Ja Seong Bae, Sohee Lee, Min-Hee Kim, Dong-Jun Lim, Youn Soo Lee, Chan Kwon Jung
International Journal of Endocrinology.2015; 2015: 1. CrossRef
BRAF Immunohistochemistry Using Clone VE1 is Strongly Concordant with BRAFV600E Mutation Test in Papillary Thyroid Carcinoma
Jung-Soo Pyo, Jin Hee Sohn, Guhyun Kang
Endocrine Pathology.2015; 26(3): 211. CrossRef
Pathologie de la thyroïde. Cas no 3. Carcinome papillaire de la thyroïde, variante à cellules hautes
Emmanuelle Leteurtre
Annales de Pathologie.2015; 35(5): 402. CrossRef

Author index